Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer

BACKGROUND: We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). METHODS: TTP RNA expression was measured in an RP cohort of patients treated at Moffitt Cance...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Epidemiol Biomarkers Prev
Main Authors: Rounbehler, Robert J., Berglund, Anders E., Gerke, Travis, Takhar, Mandeep M., Awasthi, Shivanshu, Li, Weimin, Davicioni, Elai, Erho, Nicholas G., Ross, Ashley E., Schaeffer, Edward M., Klein, Eric A., Karnes, R. Jeffrey, Jenkins, Robert B., Cleveland, John L., Park, Jong Y., Yamoah, Kosj
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214732/
https://ncbi.nlm.nih.gov/pubmed/30108099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-18-0369
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares